Gene fusions play critical roles in the development and progression of prostate cancer, and have been used as molecular biomarkers for diagnosis of the malignant disease. To further explore the novel fusions in prostate cancer, we performed targeted RNA capture and next-generation sequencing in a cohort of 52 prostate cancer patients, identified and validated 14 fusion events (7 types of fusion genes) in 12 cases, including three novel fusion genes. We characterized a chromosome rearrangement-induced trigenic KLK2-DGKB-ETV1 fusion, which may function as a noncoding RNA to upregulate the expression of the wild-type ETV1 protein in the tumor tissue. Additionally, we detected two novel fusion forms of HNRNPA2B1-ETV1 and SLC45A2-AMACR fusions, respectively. Interestingly, fusion events participated by kinase genes, which frequently occurred in other human cancers, were not present in these prostate cancer cases, suggesting discrepant gene fusion patterns in different cancers. These findings expand the genetic spectrum of prostate cancer and provide insight into diagnosis of this prevalent disease.
Introduction
Prostate cancer is one of the most frequently occurred diseases among men, which leads to considerable cancer-related death in aging males [1] . Currently, the main treatments for prostate cancer are prostatectomy, radiation, and androgen ablation, however, the overall mortality rate remains high due to resistance of some patients to androgen ablation therapy [2, 3] . Previous studies have uncovered the critical role of genetic variants in the tumorigenesis of prostate cancer [4, 5] . Thus, for diagnosis, there remains a compelling need to decode novel genetic variants underlining pathogenesis of the cancer.
Approximately 50%-60% of prostate cancers harbor recurrent gene fusions [6] , typically fusing the 5′ genomic regulatory elements, controlled by androgen, to members of the ETS family of transcription factors, such as ERG, ETV1, ETV4, and ETV5 [7] [8] [9] . TMPRSS2-ERG, the most common fusion gene in prostate cancer, was found to occur in 40%-70% prostate cancer patients [7] . Gene fusions participated by non-ETS genes were also reported in prostate cancer [10] , and most of them occurred at a relatively low frequency and were often accompanied by TMPRSS2-ERG fusion gene [11] . In recent years, next-generation sequencing, with its high throughput, accelerated the progress of genetic studies on human cancers. In order to identify novel fusion partners in prostate cancer, we designed a panel to target 65 genes frequently translocated in prostate cancer or other human cancers, and performed targeted RNA capture and next-generation sequencing in 52 prostate cancer patients. After validation by reverse transcription polymerase chain reaction (RT-PCR) and Sanger sequencing, we identified 14 gene fusion events in 12 prostate cancer patients including three novel fusion genes, which expands the genetic spectrum and provides insight into diagnosis of this prevalent disease.
Materials and Methods

Clinical samples and nucleic acid extraction
One hundred and four fresh-frozen prostate cancer and adjacent normal tissues were collected from 52 male patients who underwent tumor surgical resection in the First Affiliated Hospital of Shenzhen University. To confirm the diagnosis, H&E (hematoxylin-eosin) slides of frozen carcinoma tissues and their corresponding normal tissues were further reviewed by two experienced pathologists. Total RNA and genomic DNA were extracted from frozen tissues using TRIzol reagent (Invitrogen, Carlsbad, USA) and DNeasy Blood & Tissue Kit (Qiagen, Dusseldorf, Germany), respectively. The study was approved by the Ethical Review Board of the hospital, and tissues and clinical data were collected after patients provided informed consent.
Targeted RNA sequencing
Sixty-five target genes which were frequently translocated in prostate cancer or other human cancers were selected by mining the existing databases (Supplementary Table S1 ), including the Catalogue of Somatic Mutation in Cancer (COSMIC) database and The Cancer Genome Atlas (TCGA), as well as published articles in the field [12] [13] [14] [15] [16] [17] [18] . About 2 μg of RNA was reverse transcribed into cDNA using NEB Protoscript II reverse-transcriptase (New England Biolabs, Ipswich, USA). The second strand of cDNA was synthesized by using NEBNext mRNA second strand synthesis module (New England Biolabs). The double-stranded cDNA was further purified using DNA Clean & Concentrator Kit (Zymo research, Los Angeles, USA) and fragmented to 150-200 bp by a Bioruptor sonicator (Diagenode, Liege, Belgium). The sonicated double-stranded cDNA fragments were further used for the preparation of indexed Illumina libraries according to the standard Illumina library preparation protocol (Illumina, San Diego, USA), including end repairing, dA-tailing, adapter-ligation, and amplification. The indexed Illumina libraries were hybridized with biotin-labeled RNA probes, and captured using Dynabeads MyOne streptavidin T1 (Invitrogen). The enriched libraries were amplified and sequenced on an Illumina HiSeq 4000 sequencer (Illumina) to obtain paired-end reads of 150 bp.
Identification and validation of gene fusions
Gene fusion candidates were identified and filtered using FusionCatcher [19] with default parameters by detecting read pairs discordantly mapping to two different genes. The breakpoints of fusion genes identified by targeted RNA sequencing were further validated by PCR-based amplification and Sanger sequencing. Primer sequences of PCR were listed in Supplementary Table S2 .
Targeted DNA sequencing
Probes were designed to cover genomic areas nearby the breakpoints of RNA fusion, amplified and labeled by PCR with 20% biotindUTP. About 1 μg of genomic DNA was prepared for genomic DNA libraries according to the Illumina DNA library protocols (Illumina). The indexed Illumina libraries were hybridized with biotin-labeled DNA probes, and captured using Dynabeads MyOne streptavidin T1 (Invitrogen). The enriched libraries were amplified and sequenced on the Illumina Solexa HiSeq 4000 sequencer to obtain paired-end reads of 150 bp.
Identification and validation of structure variations
Structure variations (SVs) were identified using CREST with a default set of parameters [20] based on local assembly of the unmapped bases from overlapping split reads. The identified SVs were further manually reviewed using Integrative Genomics Viewer [21] , and validated by PCR-based amplification and Sanger sequencing. PCR primers for validation of SVs were listed in Supplementary Table S3 .
Real-time RT-PCR assay
About 1 μg of RNA was reverse transcribed using M-MLV Reverse Transcriptase (Promega, Madison, USA). Primers for real-time RT-PCR were listed in Supplementary Table S4 . The 20 μl PCR reaction system consisted of 10 μl 2×UltraSYBR Mixture (CWBio, Beijing, China), 4 μl forward and reverse primer (2 μM each), and 4 μl cDNA (with 10 times dilution). Thermal cycling conditions were as follows: an initial denaturation at 95°C for 10 min followed by 40 cycles at 95°C for 30 s and 60°C for 1 min. Melting curve was performed to analyze the quality of the PCR products. Relative mRNA levels were calculated with ΔΔCt method using GAPDH for normalization.
Western blot analysis
Proteins were extracted using RIPA Lysis Buffer (CWBio) containing protease inhibitors cocktail (Roche, Basel, Switzerland). Protein concentrations were measured by using a BCA protein concentration assay kit (Beyotime, Shanghai, China). Lysates containing 20 μg of protein were subject to 10% SDS-PAGE. The separated proteins were transferred to a PVDF membrane (Merck Millipore, Massachusetts, USA) followed by incubation with primary antibodies against ETV1 Ab H-70 (sc-28681; Santa Cruz Biotechnology, Santa Cruz, USA) and GAPDH (sc-32233; Santa Cruz Biotechnology) at 4°C overnight, respectively. The membranes were then washed and incubated with HRP-conjugated anti-rabbit (Cell Signaling, Boston, USA) and antimouse (Cell Signaling) secondary antibody at room temperature for 1 h, respectively. Signals were detected by using a FluorChem HD2 system (Proteinsimple, San Francisco, USA).
Results
Identification of gene fusions in prostate cancer patients
To investigate the gene fusions occurred in prostate cancer, we designed a panel to target genes (65) which were frequently fused in prostate cancer or other malignant tumors ( Supplementary  Table S1 ), and performed targeted RNA sequencing in 52 prostate cancer samples. An average of 9.70 GB sequencing data was generated for each sample. After validation by RT-PCR and Sanger sequencing, a total of 14 fusion events (7 types of fusion genes) in 12 patients were identified, including three novel fusion genes ( Table 1) , and TMPRSS2-ERG fusion (exon 1 of TMPRSS2 fused to exon 4 of ERG) was the most frequently occurred fusion gene (9.6%) in our cohort.
Characterization of a novel KLK2-DGKB-ETV1 fusion gene
From the targeted RNA sequencing data, we identified KLK2-DGKB and DGKB-ETV1 fusion genes, and both of the two fusions were found to occur in patient T52 after PCR validation of exon junctions in each sample. When we manually reviewed the mapping data using Integrative Genomics Viewer (IGV), we found sequencing reads spanning KLK2, DGKB, and ETV1 gene, suggesting that there may exist a triple fusion participated by these three genes. We identified the triple fusion (KLK2-DGKB-ETV1), and confirmed it to be somatically occurred in the T52 sample by RT-PCR and Sanger sequencing (Fig. 1A) . After Sanger sequencing data analysis for the amplified full length transcript of KLK2-DGKB-ETV1 fusion, we found that the fusion was rearranged by exon 1 of KLK2, exon 7 of DGKB, and exon 7-14 of ETV1 (Fig. 1B) .
To detect whether the fusion event occurred at the chromosome level, we designed a panel to target genomic regions nearby intron 1 of KLK2, intron 6, and intron 7 of DGKB, and performed targeted DNA sequencing in tumor tissue of patient T52. We detected chimeric sequencing reads spanning intron 1 of KLK2 and intron 6 of DGKB, and sequencing reads spanning intron 7 of DGKB and intron 6 of ETV1, respectively (Fig. 1C) . The chromosome rearrangement was further confirmed by PCR and Sanger sequencing (Fig. 1D) . Thus, the KLK2-DGKB-ETV1 gene fusion was generated by the complex chromosome rearrangement participated by KLK2, DGKB, and ETV1.
To evaluate the impact of the KLK2-DGKB-ETV1 fusion gene on gene expression of ETV1, we performed real-time RT-PCR in the tumor and matched normal tissue of patient T52. Primers were designed to amplify fragments in ETV1 exon 4-5 (upstream of the fusion site) and exon 8-9 (downstream of the fusion site), respectively. Expression level of ETV1 downstream the fusion site was significantly up-regulated in tumor tissue with a 21-fold increase, while expression level upstream the fusion site only showed a 1.7-fold increase, indicating that the fusion transcript was highly expressed (Fig. 2A) .
With the analysis of reading frame of the KLK2-DGKB-ETV1 fusion transcript, we found that translation from the first ATG start codon of the fusion transcript would encounter a stop codon in exon 7 of DGKB (Fig. 2B) , resulting in a predicted peptide with only 32 amino acids. Alternatively, translation from the ATG in exon 7 of ETV1 of the fusion transcript might generate an N-terminal truncated ETV1 (dETV1) protein. To evaluate whether the fusion transcript could generate a dETV1 protein, we performed western blot analysis in tumor and matched normal prostate tissues of patient T52. We did not observe a blot band to support the existence of dETV1 protein (Fig. 2C) , suggesting that the KLK2-DGKB-ETV1 fusion transcript was a non-coding RNA. Interestingly, the level of the wild-type ETV1 protein was up-regulated in the tumor tissue. Considering that the fusion transcript retained an integrated 3′ UTR sequence of ETV1, we speculated that it may serve as RNA sponge to absorb miRNAs that target the 3′ UTR sequence of wildtype ETV1 mRNA, thereby up-regulating the expression level of wild-type ETV1 protein.
Characterization of a novel form of HNRNPA2B1-ETV1 fusion gene
A novel form of HNRNPA2B1-ETV1 gene fusion was identified in patient T47, with exon 1-7 of HNRNPA2B1 rearranged with exon 10-14 of ETV1 (Fig. 3A) . Validation in the tumor and matched normal tissue of patient T47 revealed that the gene fusion was a somatic genetic variant. HNRNPA2B1-ETV1 gene fusion has been reported in prostate cancer [22] , with exon 1 of HNRNPA2B1 integrated with exon 4-14 of ETV1, and HNRNPA2B1-ETV1 fusion protein only contained two amino acids translated from HNRNPA2B1. Unlike the previously reported fusion form, the novel fusion protein identified in our study was predicted to contain two RNA binding domains, RNA recognition motif 1 (RRM1) and RRM2 of HNRNPA2B1 protein, and the integrated ETS DNA-binding domain of ETV1 protein (Fig. 3B) .
Characterization of a novel form of SLC45A2-AMACR fusion gene
Two isoforms of the SLC45A2-AMACR fusion transcript were identified in patient T1, with exon 1-2 (known form) and exon 1-4 (novel form) of SLC45A2 fused with exon 2-5 of AMACR, respectively (Fig. 4A) . The known form of SLC45A2-AMACR fusion gene has been reported at a high prevalence (7.2%) in prostate cancer in a previous study [23] , which was predicted to generate a fusion protein containing 4 of 12 transmembrane domains of the membrane transporter protein SLC45A2, and the α-methylacyl-CoA racemase domain from AMACR. The novel form was a newly identified transcript, which generated a frameshift protein with 7 of 12 transmembrane domains of SLC45A2 (Fig. 4B) .
Discussion
The development of next-generation sequencing has accelerated the pace of identification and characterization of novel genetic variants in human cancers. Benefiting from that, gene fusions, identified in a series of human cancers, have been recognized as important diagnostic molecular markers for human malignancies [24] . Here, we conducted targeted RNA sequencing in a cohort of 52 prostate cancer patients, and identified 14 fusion events in 12 patients, including three newly identified fusion genes. TMPRSS2-ERG fusion was the most frequently occurred fusion gene (9.6%) in our cohort, while its prevalence in Caucasian prostate, African-Americans and Japanese cancer patients was about 50%, 31.3%, and 15.9%, respectively [25] . Previous studies also reported a low prevalence of TMPRSS2- 
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chr1:205630989-chr1:205593019-T10, T19 ERG fusion in Chinese population [15] . Therefore, the prevalence of TMPRSS2-ERG fusion varied between different populations and geographic regions in prostate cancer. Following ERG, ETV1 is the most frequently over-expressed ETS gene in a subset of clinical prostate cancers [26] . In our study, we identified a novel somatic tri-fusion gene (KLK2-DGKB-ETV1), with exon 1 of KLK2 fused to exon 7 of DGKB and followed by exon 7-14 of ETV1. The result of targeted DNA sequencing further demonstrated that this fusion event was caused by chromosome rearrangement. Instead of generating chimeric fusion protein or a dETV1 protein, KLK2-DGKB-ETV1 fusion transcript was proved to be a non-coding RNA by western blot analysis. We did not observe dramatic up-regulation of the ETV1 wild-type mRNA in the tumor tissue, while the protein level of wild-type ETV1 was upregulated. Thus, it was likely that the fusion transcript may serve as competitive endogenous RNA to competitively absorb miRNAs targeting 3′ UTR of ETV1 to upregulate the protein level of wild-type ETV1 protein, although further evidences is needed.
TMPRSS2-ERG
HNRNPA2B1, which belongs to the A/B subfamily of ubiquitously expressed heterogeneous nuclear ribonucleoproteins, was frequently fused with ETV1 in prostate cancer [22] . We found a novel form of HNRNPA2B1-ETV1 fusion gene in one patient, with exon 1-7 of HNRNPA2B1 fused to exon 10-14 of ETV1. These two genes locate on the same strand of chromosome 7, and have been reported to be involved in another form of fusion in prostate cancer, with exon 1 of HNRNPA2B1 rearranged with exon 4-14 of ETV1 [22] . In this fusion form, only two amino acids of HNRNPA2B1 contributed to the HNRNPA2B1-ETV1 fusion protein, providing a non-tissue-specific promoter to drive the high transcription level of HNRNPA2B1-ETV1 fusion [22] . In contrast, the novel HNRNPA2B1-ETV1 fusion protein detected in our research contains two repeats of quasi-RRM domains that could bind to RNAs [27] . In addition, the fusion protein also retained ETS DNA-binding domain of ETV1, and may bind to specific DNA sequences and regulate the transcription of target genes.
SLC45A2-AMACR fusion gene has been reported in 7.2% of prostate cancer patients, with exon 1-2 of SLC45A2 fused to exon 2-5 of AMACR [23] . In this study, we found a novel gene fusion form of SLC45A2-AMACR, with exon 1-4 of SLC45A2 rearranged with exon 2-5 of AMACR. The known form of fusion protein contained four transmembrane domains of SLC45A2 and an α-methylacyl-CoA racemase domain of AMACR, while the novel SLC45A2-AMACR fusion gene generated a frameshift transcript, which was predicted to encode a 3′ truncated protein only reserving seven transmembrane domains of SLC45A2.
Androgen and androgen receptor are the key regulators in the growth of normal prostate cells and in the development and progression of prostate tumors [28] . In human prostate cancer, a series of androgen receptor target genes are fused to oncogenic transcription factors of the ETS family [14] . Androgen signaling also leads to DNA double-strand breaks and TMPRSS2-ERG rearrangements through androgen receptor-mediated recruitment of topoisomerase 2B (TOP2B) [29] . Besides TMPRSS2, SLC45A3 which was found to fuse with other genes in prostate cancer was also regulated by androgen receptor [16] . Gene fusions of the 5′ untranslated region of the androgen-regulated gene TMPRSS2 and the ETS (E26 transformation-specific) family members were reported to frequently occur in almost half of prostate cancer cases [7, 14] . Recently, Lin et al. [30] and Mani et al. [31] found that the binding of androgen receptor to DNA promoted the site-specific DNA double-stranded breaks. Therefore, androgen receptor may induce the chromosomal translocations in TMPRSS2 gene by binding to DNA, which may explain why TMPRSS2-ETS fusions are restricted to the prostate cancer. Similar to TMPRSS2-ETS fusions, other prostatespecificity fusions with ETS family members are also induced by androgen regulation [22] .
Functional consequences of gene fusions in human cancers could be summarized into several types, including protein kinase, transcription factor, metabolism, and signaling pathway [13] . Large-scale genomic and transcriptomic characterization of prostate cancer have revealed that gene fusions in prostate cancer mainly influence the function of ETS transcription factors. Although a large number of kinase genes were found to frequently rearrange in other human cancers, we did not identify gene fusions participated by kinase gene in our cohort, demonstrating that gene fusions in prostate cancer mainly influenced the function of transcription factors.
In conclusion, we have identified and characterized 14 fusion events including three novel fusion genes and one chromosome rearrangement-induced trigenic fusion in prostate cancers, which expands the genetic spectrum and provides insight into the diagnosis of this prevalent disease.
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